Overview
Tirzepatide 20mg provides a larger quantity of the dual GLP-1/GIP receptor agonist in a single lyophilised vial, making it ideal for researchers conducting extended protocols or multi-sample studies. The compound targets both incretin receptors simultaneously, offering a distinct pharmacological profile compared to single-receptor agonists.
Nova Biolabs holds Tirzepatide 20mg in Indonesia domestic stock, ensuring fast dispatch with no international shipping delays. Research-grade purity, verified by HPLC.
Tirzepatide 20mg is currently in stock and available for research order with domestic dispatch from Indonesia.
Key Research Areas
Extended Protocol Research
The 20mg vial is suited to researchers running longer experimental timelines or multiple parallel experiments requiring consistent compound batches.
Dose-Response Studies
Allows researchers to explore a wider concentration range within a single vial, supporting dose-response curve analysis in cellular models.
Receptor Co-Activation Studies
Tirzepatide's dual-receptor profile enables direct study of GLP-1 and GIP receptor co-activation and its downstream signalling effects.
Comparative Incretin Research
Frequently used alongside semaglutide in comparative studies examining the additional effect of GIP receptor engagement on metabolic signalling.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 20mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | Indonesia domestic stock |
| Research use | In vitro / laboratory use only |
| Availability | In Stock |
Quality documentation
Testing documents must match the product and batch supplied. We do not present a generic report as proof for every batch.
See our testing policy and request a batch report →